Tag Archives: Treatment

FDA Approves Eysuvis (loteprednol etabonate) Ophthalmic Suspension for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

FDA Approves Eysuvis (loteprednol etabonate) Ophthalmic Suspension for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease WATERTOWN, Mass.–(BUSINESS WIRE)–Oct. 27, 2020– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug… Read More »

FDA approves Gilead’s remdesivir as coronavirus treatment

The Food and Drug Administration on Thursday approved Gilead Sciences‘ antiviral drug remdesivir as a treatment for the coronavirus. In May, the FDA granted the drug an emergency use authorization, allowing hospitals and doctors to use the drug on patients hospitalized with the disease even though the drug has not been formally approved by the… Read More »

Melatonin — A Standard Treatment Adjunct for COVID-19?

According to a June 2020 research paper,1 melatonin2,3 may be an important adjunct to COVID-19 treatment. Incidentally, while not emphasized, melatonin is an optional addition to the highly effective MATH+ protocol promoted by the Front Line COVID-19 Critical Care Working Group (FLCCC).4 President Trump’s COVID-19 treatment was also said to include melatonin supplementation. The authors… Read More »

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »